The Regeneron Biotechnology company logo is seen displayed on a smartphone. (Igor Golovniov/SOPA Images/LightRocket via Getty Images) · SOPA Images via Getty Images "Regeneron intends to acquire ...

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.

BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing ...

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.

Regeneron Pharmaceuticals said on Monday a single dose of its antibody cocktail reduced the risk of contracting Covid-19 by 81.6 percent in a late-stage trial, in the two to eight months period ...

The Co-Founder, President and Chief Scientific Officer of Regeneron, Dr. George Yancopoulos, joins Hallie Jackson after President Trump was treated with his company's antiviral cocktail.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.

Regeneron said earlier this month it had around 50,000 doses of its treatment ready for distribution. The federal government agreed in June to buy up to 300,000 doses of the antibody cocktail for ...

In the latest trading session, Regeneron (REGN) closed at $610.09, marking a -0.71% move from the previous day. This change was narrower than the S&P 500's daily loss of 0.92%. At the same time ...

TARRYTOWN, N.Y., Jan. 10, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2019 financial and operating ...